JP2018193377A5 - - Google Patents

Download PDF

Info

Publication number
JP2018193377A5
JP2018193377A5 JP2018131186A JP2018131186A JP2018193377A5 JP 2018193377 A5 JP2018193377 A5 JP 2018193377A5 JP 2018131186 A JP2018131186 A JP 2018131186A JP 2018131186 A JP2018131186 A JP 2018131186A JP 2018193377 A5 JP2018193377 A5 JP 2018193377A5
Authority
JP
Japan
Prior art keywords
composition
allopregnanolone
subject
administered
sulfobutylether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018131186A
Other languages
English (en)
Japanese (ja)
Other versions
JP6966981B2 (ja
JP2018193377A (ja
Filing date
Publication date
Priority claimed from JP2015545458A external-priority patent/JP2016501876A/ja
Application filed filed Critical
Publication of JP2018193377A publication Critical patent/JP2018193377A/ja
Publication of JP2018193377A5 publication Critical patent/JP2018193377A5/ja
Priority to JP2021108255A priority Critical patent/JP7744166B2/ja
Application granted granted Critical
Publication of JP6966981B2 publication Critical patent/JP6966981B2/ja
Priority to JP2023125962A priority patent/JP2023133494A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018131186A 2012-11-30 2018-07-11 ステロイドの抗痙攣活性 Active JP6966981B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021108255A JP7744166B2 (ja) 2012-11-30 2021-06-30 ステロイドの抗痙攣活性
JP2023125962A JP2023133494A (ja) 2012-11-30 2023-08-02 ステロイドの抗痙攣活性

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732252P 2012-11-30 2012-11-30
US61/732,252 2012-11-30
JP2015545458A JP2016501876A (ja) 2012-11-30 2013-11-27 ステロイドの抗痙攣活性

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015545458A Division JP2016501876A (ja) 2012-11-30 2013-11-27 ステロイドの抗痙攣活性

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021108255A Division JP7744166B2 (ja) 2012-11-30 2021-06-30 ステロイドの抗痙攣活性

Publications (3)

Publication Number Publication Date
JP2018193377A JP2018193377A (ja) 2018-12-06
JP2018193377A5 true JP2018193377A5 (enExample) 2019-05-09
JP6966981B2 JP6966981B2 (ja) 2021-11-17

Family

ID=50828483

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015545458A Withdrawn JP2016501876A (ja) 2012-11-30 2013-11-27 ステロイドの抗痙攣活性
JP2018131186A Active JP6966981B2 (ja) 2012-11-30 2018-07-11 ステロイドの抗痙攣活性
JP2021108255A Active JP7744166B2 (ja) 2012-11-30 2021-06-30 ステロイドの抗痙攣活性
JP2023125962A Pending JP2023133494A (ja) 2012-11-30 2023-08-02 ステロイドの抗痙攣活性

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015545458A Withdrawn JP2016501876A (ja) 2012-11-30 2013-11-27 ステロイドの抗痙攣活性

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021108255A Active JP7744166B2 (ja) 2012-11-30 2021-06-30 ステロイドの抗痙攣活性
JP2023125962A Pending JP2023133494A (ja) 2012-11-30 2023-08-02 ステロイドの抗痙攣活性

Country Status (7)

Country Link
US (6) US20150313915A1 (enExample)
EP (2) EP2925327B1 (enExample)
JP (4) JP2016501876A (enExample)
AU (4) AU2013352141B2 (enExample)
DK (1) DK2925327T3 (enExample)
ES (1) ES2973320T3 (enExample)
WO (1) WO2014085668A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
ES2973320T3 (es) 2012-11-30 2024-06-19 Univ California Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
CN113527400B (zh) 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
BR112017010430A2 (pt) * 2014-11-18 2017-12-26 Pixarbio Corp composição para tratar dor aguda, pós-operatória ou crônica em um indivíduo, método para tratar um indivíduo tendo dor aguda, pós-operatória ou crônica e kit para produzir a composição
ME03749B (me) 2014-11-27 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
CA3254865A1 (en) * 2015-02-06 2025-05-28 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
EP3280420B1 (en) * 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
CN107949383B (zh) 2015-08-18 2022-08-23 加利福尼亚大学董事会 用于成像的含氮氧化合物的淀粉样蛋白结合剂
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
RU2766155C2 (ru) * 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
US10858338B2 (en) 2016-03-15 2020-12-08 The Regents Of The University Of California Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH)
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
SG11202001749SA (en) * 2017-09-05 2020-03-30 Eagle Pharmaceuticals Inc Methods of using dantrolene to treat nerve agent exposure
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3136389A1 (en) * 2019-04-05 2020-10-08 The Regents Of The University Of California Allopregnanolone compositions and uses thereof
CA3138901A1 (en) 2019-05-10 2020-11-19 Brii Biosciences, Inc. Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
CN114828889B (zh) 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
US12208103B1 (en) 2021-05-07 2025-01-28 Lipocine Inc. Compositions and methods for treating CNS disorders
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
DK0752860T3 (da) 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
AP653A (en) 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
EP1288220A3 (en) 1995-06-06 2004-07-21 Euro-Celtique Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US7630757B2 (en) 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
CN1270718C (zh) * 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
WO2002094218A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
WO2002094244A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
CA2527019A1 (en) 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
WO2005011612A2 (en) 2003-07-31 2005-02-10 The Research Foundation Of State University Of New York Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP1853234A2 (en) 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
EP2030622B1 (en) 2005-03-24 2011-02-23 Emory University Indication of dosage of progesterone in the treatment of a traumatic brain injury
AU2006235318A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US20080026918A1 (en) * 2006-07-27 2008-01-31 Michael Lemke Athletic training device with multi-directional movement
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
US20080243022A1 (en) 2007-03-30 2008-10-02 Donnett James G Seizure prediction using brain signal telemetry
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2167098B1 (en) 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
CA2698172C (en) * 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
JP2011507800A (ja) 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのampa受容体アンタゴニスト
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
SMT202000257T1 (it) 2008-10-10 2020-07-08 Vm Discovery Inc Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie
EP2376073A2 (en) 2008-11-30 2011-10-19 Oron Zachar Dermal application of vasoconstrictors
US20100168603A1 (en) 2008-12-23 2010-07-01 Himes David M Brain state analysis based on select seizure onset characteristics and clinical manifestations
WO2010088409A2 (en) 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
CA2753641C (en) * 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
WO2010107922A1 (en) 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US8697678B2 (en) * 2010-01-21 2014-04-15 Drawbridge Pharmaceuticals Pty Ltd Anaesthetic formulation
RU2576506C2 (ru) 2010-11-03 2016-03-10 Санофи-Авентис Дойчланд Гмбх Игольчатая канюля, содержащая лекарственный препарат
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
CA2843436A1 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
RU2014121785A (ru) 2011-11-29 2016-01-27 Амино Ап Кемикал Ко., Лтд. Композиция, содержащая виценин-2, обладающая благоприятным воздействием на неврологическую или когнитивную функцию
SMT202000008T1 (it) * 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
ES2973320T3 (es) 2012-11-30 2024-06-19 Univ California Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2017066240A1 (en) 2015-10-14 2017-04-20 The Regents Of The University Of California Enhancing beta cell replication and/or survival
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
IL265225B (en) 2016-09-07 2022-08-01 Glia Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens

Similar Documents

Publication Publication Date Title
JP2018111728A5 (enExample)
JP2014530874A5 (enExample)
JP2017149726A5 (enExample)
JP2012193216A5 (enExample)
JP2020530857A5 (enExample)
JP2014518275A5 (enExample)
JP2013505205A5 (enExample)
JP2015505564A5 (enExample)
JP2013147511A5 (enExample)
JP2015187157A5 (enExample)
JP2010525050A5 (enExample)
JP2016530291A5 (enExample)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
JP2017014206A5 (enExample)
JP2018172440A5 (enExample)
JP2020507587A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2021529829A5 (enExample)
JP2020500864A5 (enExample)
JP2013166781A5 (enExample)
JP2015522603A5 (enExample)
JP2017514858A5 (enExample)
JP2022532038A5 (enExample)
JP2007119497A5 (enExample)
JP2016505050A5 (enExample)